Clinical Trials Browser

Phase 2 × Triple Negative Breast Neoplasms × Radiotherapy × Clear all

NCT06492759 2026-04-17

High Dose Radiation Therapy With Pembrolizumab and Chemotherapy for the Treatment of Patients With PD-L1 Positive Metastatic Triple Negative Breast Cancer

Phase 2 Recruiting

29 enrolled

Breast

Triple Negative Breast Neoplasms

NCT01750073 2025-11-18

Paclitaxel & Cyclophosphamide With or Without Trastuzumab Before Surgery in Treating Previously Untreated Breast Cancer

Phase 2 Active not recruiting

92 enrolled 17 charts

Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT04837209 2025-10-01

NADiR

Phase 2 Active not recruiting

32 enrolled

Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT05491226 2025-08-27

Reinvigorating TNBC Response to Immunotherapy With Combination Myeloid Inhibition and Radiation

Phase 2 Active not recruiting

35 enrolled

Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT07015853 2025-08-27

ASTRAEA: ReinvigorAting ReSponse To ImmunotheRApy in MEtAstatic TNBC With Combination Myeloid Inhibition and Radiation

Phase 2 Not yet recruiting

34 enrolled

Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT07104266 2025-08-05

Triple Negative Breast Cancer and Celecoxib. Pilot Study

Phase 2 Recruiting

30 enrolled

Breast

Triple Negative Breast Neoplasms

NCT05233696 2022-12-06

Radiotherapy in Combo With Chemo and Immunotherapy in Patients With PD-L1 Positive Metastatic TNBC

Phase 2 Withdrawn

Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT03872505 2021-08-25

PANDoRA

Phase 2 Withdrawn

Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT01375023 2015-06-22

Allogenic Haematopoietic Cell Transplantation for Patients With Refractory "Triple Negative" Breast Cancer

Phase 2 Terminated

3 enrolled

Breast

Breast Neoplasms, Triple Negative Breast Neoplasms